Kyverna Therapeutics (NASDAQ: KYTX) updates board after exit

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. reported a change in its board leadership. Steve Liapis, Ph.D. notified the company on September 19, 2025 that he will resign as a member of the board of directors and all related committees, effective September 30, 2025. The company states that his resignation is not due to any disagreement with its operations, policies, or practices.

After his departure, the size of the board will be reduced from eight to seven directors. The board has appointed current director Christi Shaw to the Audit Committee to fill the vacancy created by Dr. Liapis’ resignation. The board also expressed appreciation for Dr. Liapis’ years of service and contributions.

0001994702false00019947022025-09-192025-09-19

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 19, 2025

Kyverna Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41947	83-1365441
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5980 Horton St., Suite 550
Emeryville, California				94608
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 925-2492

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		KYTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 19, 2025, Steve Liapis, Ph.D. notified the board of directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) of his decision to resign from his position as a member of the Board and all committees thereof, effective September 30, 2025. Dr. Liapis’ resignation is not due to any disagreement with the Company relating to any of the Company’s operations, policies or practices.

The Board thanks Dr. Liapis for his years of service and valuable contributions to the Company.

Effective upon Dr. Liapis’ resignation, the size of the Board will be reduced from eight to seven directors. The Board has appointed Christi Shaw, a current member of the Board, to the Audit Committee of the Board to fill the vacancy on the committee upon Dr. Liapis’ resignation.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
 

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			KYVERNA THERAPEUTICS, INC.
Date:	September 25, 2025	By:	/s/ Warner Biddle
			Warner Biddle Chief Executive Officer

FAQ

What board change did Kyverna Therapeutics (KYTX) disclose?

Kyverna Therapeutics disclosed that Steve Liapis, Ph.D. has decided to resign from its board of directors and all board committees, effective September 30, 2025.

Why is director Steve Liapis resigning from Kyverna Therapeutics' board?

The company states that Dr. Liapis’ resignation is not due to any disagreement with Kyverna Therapeutics regarding its operations, policies, or practices.

How will the Kyverna Therapeutics (KYTX) board size change after the resignation?

Effective upon Dr. Liapis’ resignation on September 30, 2025, the Kyverna Therapeutics board will be reduced in size from eight to seven directors.

Who will replace Steve Liapis on Kyverna Therapeutics’ Audit Committee?

The board has appointed Christi Shaw, a current director, to the Audit Committee to fill the vacancy created by Dr. Liapis’ resignation.

Does Kyverna Therapeutics mention any disputes related to the director’s resignation?

No. Kyverna Therapeutics explicitly notes that Dr. Liapis’ resignation is not due to any disagreement with the company’s operations, policies, or practices.

What type of SEC filing did Kyverna Therapeutics (KYTX) use to report this change?

The company reported the board and committee changes in a Form 8-K under the item covering departures and appointments of directors and certain officers.